Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits.

Capricor (NASDAQ: CAPR ) investors were hit with a 60% to 70% drop on July 27, 2026, after FDA briefing documents concluded that Deramiocel failed to demonstrate statistically significant benefits on its pre-specified cardiac endpoint. Shareholders who lost money on CAPR are encouraged to act now as Levi & Korsinsky reviews potential securities law violations. Submit loss information now or call (212) 363-7500.

The investor impact centers on Deramiocel's cardiac efficacy data. In a May 7, 2026 press release, Capricor stated that Deramiocel slowed cardiac decline by approximately 91% compared to placebo, with statistical significance. The July 27, 2026 FDA briefing documents addressed the same cardiac endpoint and concluded that the pivotal trial failed to demonstrate statistically significant benefit under the pre-specified analysis.

CAPR shares fell approximately 60% to 70% after the documents became public ahead of the July 29, 2026 advisory committee meeting. Levi & Korsinsky is reviewing losses suffered by CAPR investors tied to the July 27, 2026 decline and the Company's prior statements concerning Deramiocel's cardiac efficacy. If you suffered losses in Capricor, request your loss review today or call (212) 363-7500.